Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice

BACKGROUND: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH) are serious conditions and are being diagnosed at an increased rate. The etiology of these hepatic disorders is not clear but involves insulin resistance and oxidative stress. Remogliflozin etabonate (Remo) is an in...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Exp Hepatol
Hoofdauteurs: Nakano, Shigeru, Katsuno, Kenji, Isaji, Masayuki, Nagasawa, Tatsuya, Buehrer, Benjamin, Walker, Susan, Wilkison, William O., Cheatham, Bentley
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2015
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4632078/
https://ncbi.nlm.nih.gov/pubmed/26628836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jceh.2015.02.005
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items